Sunitinib Efficient in Very Rare Neuroendocrine Tumor

Sunitinib Efficient in Very Rare Neuroendocrine Tumor

The utilization of the tyrosine kinase inhibitor (TKI) sunitinib (Sutent) tremendously improved development-free survival (PFS) in patients with malignant pheochromocytoma and paraganglioma (PPGL), an awfully rare neuroendocrine tumor, in line with results from the randomized FIRSTMAPPP trial. The important endpoint…